Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Data deficit denies Indonesia's poorest access to JKN

  • Ardila Syakriah


Jakarta   /   Sat, July 4 2020   /  01:00 am
The BPJS has stopped covering trastuzumab for patients treated under its state-funded National Health Insurance-Healthy Indonesia Card (JKN-KIS) scheme since April 1, arguing that the medication’s effectiveness was not empirically proven.(Shutterstock/File)

When the COVID-19 pandemic hit Indonesia in March, South Tangerang, Banten, resident Tinto Arianto Wibowo's 2-year-old son's hospital visits became even more frequent, draining him financially. His son had long suffered fevers, coughing and a lump on his neck and the hospital advised him to go to another hospital as it suspected he had COVID-19. The pandemic, however, has prevented Tinto from taking on his usual side jobs, leaving him with only the Rp 2 million (US$138.32) per month he earns as an honorarium-based worker – barely enough to feed his family of five. He immediately signed his son up for a National Health Insurance (JKN) plan, which is run by the Healthcare and Social Security Agency (BPJS Kesehatan). The South Tangerang administration later included his son as a recipient of contribution assistance (PBI) for low-income patients whose JKN premiums are ful...